

1 **Title:** Aptima Combo2-avoiding variants detected in cervical and endometrial specimens from a
2 cohort of sexually active cisgender women during 16S microbiome profiling.

3

4 **Authors:** Sangmi Jeong¹, Tammy Tollison¹, Hayden Brochu¹, Hsuan Chou¹, Tammy Yu²,
5 Priyanka Baghaie², Kacy S. Yount², Toni Darville², Xinxia Peng¹ and Catherine M. O'Connell²

6 ¹North Carolina State University

7 ²University of North Carolina at Chapel Hill

8

9 **Correspondence:** Catherine O'Connell, PhD, University of North Carolina at Chapel Hill, 8340B
10 MBRB, CB# 7509, 111 Mason Farm Road, Chapel Hill, NC 27599-7509, phone (919) 962-3422,
11 fax:(919) 966-7277, catherine.oconnell@unc.edu

12 Alternate corresponding author: Xinxia Peng, PhD, North Carolina State University, Raleigh, NC
13 27695, phone (919) 515-4481, fax: (919)-513-6464, xpeng5@ncsu.edu

14

15 **Keywords:** NAAT, chlamydia, gonorrhea, microbiome, 16S rRNA, false negative, 23S

16 **Abstract:**

17 Background: Performance of a 16S rRNA analysis of the cervicovaginal microbiome of 220
18 participants recruited into the T Cell Response against Chlamydia (TRAC) cohort between
19 February 2011 and August 2014 in Allegheny County, Pennsylvania USA surprisingly detected
20 DNA encoding chlamydial 16S rRNA in samples from seven participants who had tested
21 negatively for *Chlamydia trachomatis* (CT) and DNA encoding gonococcal 16S rRNA from five
22 participants who had tested negatively for *Neisseria gonorrhoeae* (NG) infection with the Aptima
23 Combo2 assay (Hologic).

24 Methods: We used targeted PCR amplification followed by sequencing to characterize the
25 chlamydial 23S rRNA locus and qPCR to detect gonococcal DNA in residual diagnostic swab
26 eluates or DNA used to generate 16S rRNA libraries.

27 Results: Discrepant specimens that contained chlamydial DNA carried a diagnostic-avoidant,
28 G1526A variant in the 23S rRNA locus identical to variants previously detected in Finland,
29 Denmark, and the UK. PCR validation of gonococcal DNA was confirmed for all participants who
30 had tested negatively, with stochastic effects consistent with infection levels close to the limit of
31 detection by the diagnostic assay.

32 Conclusions: These data indicate that this probe-avoidant CT mutant, and possibly others, were
33 circulating in the northeastern US prior to their detection and characterization in 2019 and
34 subsequently. Although infrequent, documentation of false negative results for CT indicates a
35 need for clinicians to consider performance of a second test that uses alternate PCR probes if
36 patients have persistent symptoms or have known contact to an infected sex partner and their
37 initial NAAT is negative.

38

39

40 **Introduction:**

41 Performing cross sectional or longitudinal research studies investigating natural immunity
42 or immunopathogenesis of sexually transmitted infections (STI) in humans can be a complex,
43 time consuming and expensive undertaking. Efforts to mine all data associated with infection or
44 disease cohorts are often extensive and protracted. Such is the case for the TRAC (T cell
45 Response Against Chlamydia) cohort, a group of 246 cisgender women at elevated risk for
46 chlamydial infection who enrolled between February 2011 and August 2014 while presenting to
47 the Allegheny County, PA Health Department's Sexually Transmitted Diseases Clinic for STI
48 testing and/or management. The TRAC study sought to profile cell mediated responses
49 associated with protection against ascending *C. trachomatis* (CT) infection or reinfection [1, 2].
50 Since completion of enrollment, data obtained from participant samples and questionnaire
51 responses have been used to profile antibody [1, 3-5], T cell antigen-specific responses [2], and
52 to determine risk factors for ascending infection. Using modern molecular techniques, we
53 quantified pathogen burden [1, 2], local cytokine secretion [6] and used genetic profiling
54 techniques to search for biomarkers predictive of disease or reinfection risk [7-9]. Secondary
55 investigations have also assessed the impact of *Mycoplasma genitalium* infection in this
56 population [10]. Fundamental to the success of these analyses has been accurate classification
57 of study participants according to infection status at enrollment and during subsequent follow up,
58 so enrollee infection status was assigned according to the outcome of an FDA-approved STI
59 diagnostic NAAT test performed at the study visit, the results of which could be used to inform
60 clinical care. Infrequently, discrepant results were observed between research PCR assays
61 detecting chlamydial loci and results obtained using the Aptima Combo 2® assay (AC2),
62 manufactured by Hologic, Inc., a commercially available nucleic acid amplification test (NAAT)
63 that is widely used to co-detect CT and *Neisseria gonorrhoeae* (NG), targeting 23S ribosomal
64 RNA (rRNA) and 16S rRNA in these bacteria, respectively. However, we could not exclude the

65 possibility of cross-contamination from the environment or chlamydia-infected specimens,
66 particularly with repurposed, reprocessed convenience samples, e.g., leftover transport medium.

67 The availability of pristine “future use” vaginal swabs collected from the same cohort and
68 stored since enrollment provided an opportunity to reexamine these discrepant results while
69 determining cervicovaginal microbiome profiles that associated with ascending chlamydial
70 infection (unpublished). We performed a 16S rRNA gene genomic DNA based microbiome
71 analysis on the entire cohort and detected chlamydial DNA in samples from seven participants
72 who had tested negatively for CT and gonococcal DNA from five participants who had tested
73 negatively for NG infection clinically. PCR amplification and subsequent sequencing using primers
74 directed against the 23S rRNA locus revealed that some of the specimens contained chlamydial
75 DNA carrying a diagnostic-avoidant single nucleotide polymorphism (SNP) that likely contributed
76 to misclassification. These data indicate that this mutant, and possibly others, were circulating in
77 the northeastern US prior to their detection and characterization in the United Kingdom and
78 Denmark in 2019 and subsequently [11-13]. Although infrequent, documentation of false negative
79 results for CT indicates a need for clinicians to consider performance of a second test that uses
80 alternate PCR probes if patients have persistent symptoms or have known contact to an infected
81 sex partner and their initial NAAT is negative. Discrepant NG detection appeared to reflect very
82 low gonococcal loads that challenged the limit of resolution for the NAAT, indicating the need to
83 consider repeat testing in patients with known exposure.

84

85 **Methods:**

86 *T Cell Response against Chlamydia (TRAC) Cohort (246 participants)*. This cohort was composed
87 of mainly young (median age, 21 years; range, 18-35 years), single (89%), African American
88 (66%) women at high risk for the acquisition of *C. trachomatis*. Criteria indicating high-risk status

89 included > 3 sexual partners in the previous 6 months, \leq 14 years of age at sexual debut, history
90 of pelvic inflammatory disease (PID), or presentation to the recruitment site with any of the
91 following: presence of mucopurulent cervicitis on exam, or sexual contact with a partner known
92 to be infected with CT or NG or non-gonococcal non-chlamydial urethritis. Women with a current
93 diagnosis of PID according to the Centers for Disease Control and Prevention guidelines were
94 excluded. Additional exclusion criteria were pregnancy, uterine procedure or miscarriage in the
95 preceding 60 days, menopause, hysterectomy, antibiotic therapy in the preceding 14 days, and
96 allergy to study medications. TRAC participants were enrolled into a longitudinal study designed
97 to investigate T cell responses important for protection from incident chlamydial infection over 12
98 months of follow-up between February 2011 and August 2014 and were recruited from the
99 Allegheny County Health Department's Sexually Transmitted Diseases Clinic, Magee-Womens
100 Hospital (MWH) Ambulatory Care Clinic, and the Reproductive Infectious Disease Research Unit
101 at MWH in Pittsburgh PA. Participants provided informed consent at the time of enrollment and
102 completed questionnaires regarding obstetric/gynecologic history, behavioral practices, sex
103 exposure, contraceptive methods, and symptoms according to study protocols. Clinical,
104 histological, and microbiological testing was performed, and blood and endometrial samples were
105 obtained after enrollment, after which all participants received single-dose agents for gonorrhea
106 (ceftriaxone, 250 mg intramuscularly) and chlamydia (azithromycin, 1 g orally). Participants in this
107 cohort were assessed for cervical and endometrial infection using Aptima Combo 2 (AC2)
108 (Hologic, Marlborough, MA) NAAT with overall infection rates of 67% and 8.5% for CT and NG,
109 respectively. *M. genitalium* (MG) infection was determined using the Aptima MG NAAT (Hologic).

110

111 *16S library construction and characterization.* Cervicovaginal swab samples available from 246
112 women enrolled in TRAC [1] were processed for 16S rRNA gene microbiome profiling
113 (unpublished). In brief, cervicovaginal microbial communities present in participant specimens

114 were profiled by sequencing the V4 region of 16S rRNA gene using Illumina sequencing. The 16S
115 rRNA amplicon sequencing data was processed at the level of inferred amplicon sequence
116 variants (ASVs) using USEARCH v11 [14]. The raw sequencing data supporting the conclusions
117 of this article is publicly available at NCBI's Short Read Archive (SRA) under BioProject accession
118 number PRJNA1136868.

119

120 *PCR template purification from residual diagnostic samples.* DNA was extracted as previously
121 published using a Quick-DNA Universal Kit (Zymo Research, Irvine, California, USA) from 100 µL
122 to 300 µL of reserved cervical swab eluates. Chlamydial and/or mycoplasmal loads were
123 measured by quantitative PCR [1] targeting the 16SrRNA gene [15] or the highly conserved
124 MG190 locus [10], respectively. Primers directed against the *parA* pseudogene [16], 16S rRNA
125 and 23S rRNA loci [17] were similarly used to validate and/or quantify NG abundance.

126

127 *PCR amplification and sequencing of 23S rRNA alleles.* Amplification conditions for detection of
128 SNPs in *C. trachomatis* 23S were as described [18]. The melting temperature was raised to 98°C
129 for optimal activation of the high fidelity, proof-reading enzyme Phusion (ThermoFisher). Samples
130 were processed independently in a dedicated PCR hood to minimize risk of cross-contamination
131 during analysis. Two rounds of amplification were required to recover sufficient product which was
132 cleaned and concentrated using a DNA Clean and Concentrate kit (Zymo) before sequencing in
133 forward and reverse directions using V3 region primers [18]. Two patient samples that had tested
134 positively using the AC2 test were also analyzed as controls. Sequences generated via Sanger
135 sequencing were aligned against the published sequence using Clone Manager Professional
136 Version 11 (Sci Ed Software LLC, Westminster, CO). Residual cervical templates were used from
137 profiled participants except for 3-209, for whom only endometrial extracted DNA remained
138 available for analysis.

139 *Statistical analysis.* The nonparametric Spearman rank correlation coefficient was calculated to
140 assess the overall correlation between CT 16S rRNA gene DNA copy numbers measured by
141 qPCR and the raw read counts of CT 16S rRNA gene from microbiome sequencing analysis using
142 R function 'cor' [19]. The LOESS (Locally Weighted Scatter-plot Smoother) curve was estimated
143 and plotted using a 'geom_smooth' function of the R 'ggplot2' package with default settings [20].
144 Abundance of NG-specific ASVs present in libraries from individuals testing positively with AC2
145 and those who tested negative were compared using a Mann-Whitney test (two tailed).

146

147 **Results:**

148 *Detection of chlamydia-derived amplicon sequence variant (ASV) in 16S libraries derived from*
149 *vaginal swabs obtained from CT negative TRAC participants.* Total DNA was extracted from
150 "future use" vaginal swabs from a total of 246 TRAC participants for inclusion in a 16S rRNA gene-
151 based sequencing analysis of the contribution of the cervicovaginal microbiome to ascending
152 chlamydial infection. Three samples were excluded based on DNA low integrity values after
153 extraction. We also excluded twenty-three samples due to the equivocal results of chlamydial
154 infection at the cervix and/or endometrium from clinical diagnostic testing. The remaining 220
155 samples were processed using the ASV-level analysis, resulting in 1,990 ASVs detected in total
156 from samples sequenced to the average depth of ~151,000 reads. Taxonomy annotations of
157 ASVs were based on sequence comparison against the 16S rRNA gene reference database RDP
158 version 19 [21] using the SINTAX algorithm [22]. We assessed the concordance of STI detection
159 by examining raw read counts of sexually transmitted pathogen-specific 16S rRNA genes vs
160 infections previously assessed by NAAT diagnostic tests (CT, NG, MG) (**Fig. 1a**) and quantified
161 via qPCR (CT [1], **Fig. 1b**). About 58% (83 of 143) samples from participants testing positively for
162 CT at enrollment had non-zero 16S rRNA gene read counts (**Fig. 1a**). Similarly, 85% (17 of 20)
163 samples from participants tested positively for NG, and 15.8% (6 of 38) samples from MG positive

164 enrollees had non-zero 16S rRNA gene read counts. Overall, there was modest correlation
165 (Spearman = 0.575) between the two CT quantification methods (**Fig. 1b**).

166 Based on clinical diagnostic results obtained at enrollment, the TRAC participants were
167 classified into three groups: 1) uninfected; 2) Endo- participants with CT infection detected only
168 in their cervical diagnostic swab; 3) Endo+ participants who tested positively for CT in both
169 cervical and endometrial diagnostic samples. No TRAC enrollees were identified who tested
170 positively only in their endometrial biopsy. Comparing ASV abundances between CT-positive
171 (Endo- and Endo+) and CT-negative (control) women, we were surprised to detect 16S ASV
172 within libraries derived from samples from women who had been assigned “uninfected” (N=7)
173 based on the results of NAAT testing (**Fig. 1a**). Furthermore, these results correlated with
174 estimated chlamydial abundance derived from a previously performed quantitative 16S PCR
175 assay (**Fig. 1b** and **Table 1**), suggesting that attributing the original results to external or cross-
176 contamination was incorrect. A review of the participants’ clinical data revealed that they were
177 largely asymptomatic, only one had reported experiencing dysuria, consistent with >10 leucocytes
178 detected per high power field in her urine sample with irregular vaginal bleeding, while one other
179 reported dyspareunia and abnormal vaginal discharge. Clinical findings upon pelvic examination
180 were unremarkable for all. Three of the seven participants within this group reported contact with
181 a CT infected partner in the three months prior to their enrollment but that they had not received
182 treatment.

183

184

Table 1. TRAC participants with discrepant clinical and molecular CT detection

Sample ID	Clinical testing (CT, MG, NG)	16S rRNA read counts in ASV analysis	16S qPCR*	
			Cx	Endo
3-101	CT-/MG-/NG-	1	78	919

3-144		16	420	87
3-145		146	128800	35
3-148		111	3839	457
3-201		55	1495	721
3-226		31	1640	105
3-209	CT-/MG+/NG-	4	13000	62680

*Chlamydial 16S rDNA copies/swab [1].

185

186 In the context of the TRAC cohort, reasons for false negative CT NAAT test results, other
187 than testing failures detected at or during performance e.g., compromised reagents or automated
188 run failure (batch specific), include inadequate sampling at the anatomical site or an unanticipated
189 flaw in the diagnostic test. All NAAT tests were run within temporal parameters appropriate for
190 clinical STI testing, so batch-specific effects did not serve as an explanation for these
191 discrepancies because the participants were not recruited contemporaneously. Testing of an
192 endometrial biopsy might result in a false negative because the entire endometrial lining is not
193 sampled, the amounts of tissue obtained may vary [8], and the region of specimen dedicated to
194 NAAT testing is small [10]. However, cervical testing, particularly when performed by highly
195 trained nurse practitioners, is robust [23, 24]. Several publications from Northern Europe have
196 reported instances of false negative testing specifically associated with the AC2 test [12, 13, 25,
197 26] arising because of probe-avoidant mutations at the chlamydial 23S rRNA locus [18].
198 Speculating that this might explain our discrepant results, we attempted to amplify the relevant
199 V3 region from cervically or endometrially derived templates that had been extracted from leftover
200 diagnostic swab eluates. In all instances we were successful using the protocol and primers used
201 by Hokynar et al. [18], further confirming the presence of chlamydial DNA in the clinical samples.
202 We detected a G-A substitution at 1523 in the samples of all seven test-discrepant participants
203 (**Fig. 2**) when these products were sequenced. NAAT positively-testing samples (N=2) from the
204 cohort were wild type at this position (data not shown). These data indicated that at least one
205 probe-avoidant variant of CT was circulating in Allegheny Co. PA between May 2012 and

206 February 2014, the time window between enrollments of our earliest and latest discrepant TRAC
207 participants.

208 16S rRNA gene microbiome analysis also revealed a total of five participants with
209 discrepant NG AC2 testing enrolled from April 2011 to July 2013 (**Fig. 1A, Table 2**), including one
210 participant, 3-209, who also tested discrepantly for CT (**Table 1**). Clinically, one participant
211 reported mild urinary symptoms with abnormal vaginal discharge and irregular bleeding and one
212 other participant reported bleeding with intercourse. Clinical findings after pelvic examination were
213 noteworthy for bleeding with cervical contact for four of five participants but were otherwise
214 unremarkable. Only one of these participants reported contact with an infected partner within the
215 preceding three months but had not received treatment.

216 The genus *Neisseria* includes a group of commensal species, *N. subflava*, *N. mucosa*, *N.*
217 *elongata*, in addition to the important human pathogens, *N. gonorrhoeae* and *N. meningitidis* with
218 the potential for genetic exchange between these naturally competent microorganisms [27] so we
219 initially speculated that the ASV detected lacked discriminatory capacity. However, alignment of
220 the 16S V4 sequence from *N. gonorrhoeae* with the 35 *Neisseria* species included in the RDP
221 v18 database, revealed that ASV ZOtu95, detected in the discrepant samples, was highly specific,
222 aligning with 100% identity between bases 535-787 of the 1544 nucleotide V4 region. This
223 suggested that the 16S ASV detected in libraries generated from the vaginal swabs reflected true
224 gonococcal infection. Next, we compared the number of ZOtu95 reads from discordant individuals
225 with those detected in libraries generated from TRAC participants with concordant NG detection
226 (Table 2) as a surrogate for pathogen load. The number of reads counted in NG+ samples ranged
227 across four orders of magnitude but participant swab samples yielding libraries with ≤ 6 counts still
228 tested positively via AC2 and no difference was detected between the groups using the non-
229 parametric Mann-Whitney test ($P=0.4116$). Low levels of infection may have contributed to
230 differential sampling of bacterial populations present at the cervix (diagnostic) and in the vagina

231 (16S analysis). Quantifying NG by qPCR in residual template was difficult because of the minimal
232 amount of cervical DNA remaining and the potential for high genetic variability between strains.
233 Using primers that targeted multicopy (16S, 23S rRNA) and single copy (ParA pseudogene) loci,
234 with genomic DNA extracted from *N. gonorrhoeae* strain FA19 as a positive control [28], we
235 performed qPCR on diagnostic swab eluates or the 16S template that remained from discrepant
236 NG+ participants (Table 2). Evaluating the performance of the primer pairs using material
237 obtained from participants testing positively for NG infection, we observed that only 8 of the 17
238 samples consistently yielded PCR product for all 3 loci, while 6, were positive for 1-2. We were
239 unsuccessful in amplifying material from the remaining 3 samples. Overall, successful
240 amplification of the targets did not reflect abundance of 16S read counts in participants' 16S rRNA
241 libraries. For samples derived from participants who had tested negatively clinically but with
242 ZOtu95 reads detected via 16S rRNA microbiome profiling, all tested positively for at least one
243 multicopy locus.

244 With no source for cross-contamination available in the lab performing the 16S rRNA
245 analysis, we also looked retrospectively at participant enrollment dates to exclude the remote
246 possibility of cross- or environmental contamination [29] occurring during sample collection or
247 NAAT testing. In only one instance did we observe enrollment of a discrepant NG- (3-121) and a
248 confirmed clinically NG+ participant within the same 48-hour window (3-120). However, the
249 presence of additional, neisserial species ASVs in the library generated from 3-120 only (Table
250 2), is inconsistent with contamination of the discrepant NG- sample by material derived from this
251 diagnostic swab.

252

253 **Discussion:**

254 This study revealed that non-congruent CT infection outcomes that we detected between
255 clinical diagnostics and 16S analysis for cervicovaginal samples collected from TRAC enrollees
256 are best explained as resulting from false negative NAAT tests. The point mutation in 23S that we
257 detected in discordant TRAC participants has been associated with reduced probe binding with
258 the original AC2 assay. The G1523A variant was detected after clinical samples in the UK were
259 screened for probe-avoiding mutants that might be in circulation [12] and also in Denmark [13].
260 This is the first report of its detection in the United States although Katz et al., reported other 23S
261 variants that mapped to A1518G or G1526A escaping detection in specimens collected in a five-
262 week window, spanning late 2019 to early 2020 (2 of 401) [30]. Our retrospective analysis
263 suggests that diagnostic-avoidant CT was already circulating in western Pennsylvania, USA by
264 2012 or possibly earlier. The first participants of the TRAC cohort enrolled in February 2011, but
265 we did not identify diagnostically discordant enrollment samples collected prior to May 2012.
266 Provided that this mutation does not impair chlamydial fitness, it is likely that it continues to
267 circulate. The first 23S SNP variant escaping detection by the AC2 assay, FI-nvCT (C1515T), is
268 still present in Finland at an estimated prevalence of 1.8% [31]. Fortunately, the deficit in the
269 clinical test has been recognized and remediated by the manufacturer via incorporation of an
270 additional chlamydial target [25] to improve reliability.

271 While discordancy between the clinical diagnostic assay for CT 23S RNA and detection
272 of CT 16S rRNA, whether by qPCR or in the 16S rRNA libraries generated for microbiome analysis
273 was ultimately elucidated by our identification of a genetic variant, the basis for the discrepancy
274 of detection of NG16S ASVs in participant samples from study participants who were diagnosed
275 NG negative via the AC2 assay is not easily explained. The NG probe of the AC2 assay is directed
276 against 16S rRNA and is both sensitive and highly specific [32-34]. Multiplex diagnostic tests have
277 been reported to have high sensitivity and high concordance with standard nucleic acid
278 amplification testing [35, 36] with a 4-in-1 test for CT, NG, *Trichomonas vaginalis*, and *M.*
279 *genitalium* receiving recent approval by the FDA [37]. False positive results for NG have been

280 obtained arising from recombination between 16S loci of *N. meningitidis*, now recognized as a
281 urogenital pathogen [38-40], and NG [41, 42]. The presence of multiple ribosomal RNA operons
282 in this genus [43] elevates the risk for even rare recombination events to become fixed in the
283 population. Should the inverse recombination event also occur, and NG acquire 16S copies from
284 other neisserial species, this could lead to reduced diagnostic sensitivity, the consequences of
285 which could negatively impact infection control and promote spread of diagnostic-avoidant
286 mutants as was observed with Swedish nvCT [44, 45]. Identification of highly conserved,
287 alternative targets for detection of NG has proven extremely challenging, so it is not surprising
288 that we were unable to positively confirm the presence of genomic DNA in all the samples.
289 However, we were also unable to amplify even multicopy targets from specimens collected from
290 participants that tested positively by clinical NAAT, raising the possibility of low abundance
291 bacteria that are asymmetrically distributed between the cervix and vaginal vault of discrepant
292 enrollees.

293 Fortunately, study participants of TRAC were not harmed by failure to detect their CT
294 and/or NG infection because all recipients were administered appropriate antibiotic therapy at
295 enrollment regardless of their NAAT-determined infection status. The availability of multiplex STI
296 testing enables pathogen-directed therapies and improved antimicrobial stewardship [46].
297 Appropriately, health care providers are moving from empiric syndromic treatment of patients at
298 risk for STIs to pathogen-specific treatment guided by results of molecular tests. Although current
299 NAATs are highly accurate, since untreated CT and NG can cause minor or no symptoms in the
300 acute phase, but lead to severe complications of chronic pelvic pain, infertility, and ectopic
301 pregnancy in women, clinicians and health department epidemiologists should remain vigilant for
302 potential CT or NG variants evading current approved NAATs such as detection of negative test
303 results in a recently exposed individual, or a decline in overall rates of infection in a particular
304 geographic location as occurred with Swedish nvCT [44, 45].

305

306 **Acknowledgements:** We thank the women who agreed to participate in this study; Ingrid Macio,
307 Melinda Petrina, Carol Priest, Abi Jett, and Lorna Rabe under direction of Harold Wiesenfeld and
308 Sharon Hillier, for their efforts in the clinic and the microbiology laboratory; and the staff at the
309 Allegheny County Health Department STD Clinic, for their efforts. We would also like to
310 acknowledge the contribution of Dr. Ian Huntress, who sadly passed away during the performance
311 of these studies.

312

313 **Financial support:** This work was supported by the National Institute of Allergy and Infectious
314 Diseases via U19 AI084024 and R01AI170959.

315

316

317 **Bibliography:**

318

319 1. Russell AN, Zheng X, O'Connell CM, Taylor BD, Wiesenfeld HC, Hillier SL, Zhong W,
320 Darville T: **Analysis of factors driving incident and ascending infection and the role**
321 **of serum antibody in *Chlamydia trachomatis* genital tract infection.** *J Infect Dis*
322 2016, **213**(4):523-531.

323 2. Russell AN, Zheng X, O'Connell CM, Wiesenfeld HC, Hillier SL, Taylor BD, Picard MD,
324 Flechtner JB, Zhong W, Frazer LC *et al*: **Identification of *Chlamydia trachomatis***
325 **antigens recognized by T cells from highly exposed women who limit or resist**
326 **genital tract infection.** *J Infect Dis* 2016, **214**(12):1884-1892.

327 3. Liu C, Mokashi Neha V, Darville T, Sun X, O'Connell Catherine M, Hufnagel K,
328 Waterboer T, Zheng X: **A machine learning-based analytic pipeline applied to**
329 **clinical and serum IgG immunoproteome data to predict *Chlamydia trachomatis***
330 **genital tract ascension and incident infection in women.** *Microbiol Spect* 2023,
331 **0**(0):e04689-04622.

332 4. Liu C, Hufnagel K, O'Connell CM, Goonetilleke N, Mokashi N, Waterboer T, Tollison TS,
333 Peng X, Wiesenfeld HC, Hillier SL *et al*: **Reduced endometrial ascension and**
334 **enhanced reinfection associated with IgG antibodies to specific *Chlamydia***
335 ***trachomatis* proteins in women at Risk for Chlamydia.** *J Infect Dis* 2021.

336 5. Darville T, Albritton HL, Zhong W, Dong L, O'Connell CM, Poston TB, Quayle AJ,
337 Goonetilleke N, Wiesenfeld HC, Hillier SL *et al*: **Anti-chlamydia IgG and IgA are**
338 **insufficient to prevent endometrial chlamydia infection in women, and increased**
339 **anti-chlamydia IgG is associated with enhanced risk for incident infection.** *Am J*
340 *Reprod Immunol* 2019, **81**(5):e13103.

- 341 6. Poston TB, Lee DE, Darville T, Zhong W, Dong L, O'Connell CM, Wiesenfeld HC, Hillier
342 SL, Sempowski GD, Zheng X: **Cervical cytokines associated with *Chlamydia***
343 ***trachomatis* susceptibility and protection.** *J Infect Dis* 2019, **220**(2):330-339.
- 344 7. Zheng X, Zhong W, O'Connell CM, Liu Y, Haggerty CL, Geisler WM, Anyalechi GE,
345 Kirkcaldy RD, Wiesenfeld HC, Hillier SL *et al*: **Host genetic risk factors for *Chlamydia***
346 ***trachomatis*-related infertility in women.** *J Infect Dis* 2021, **224**(Supplement_2):S64-
347 s71.
- 348 8. Zheng X, O'Connell CM, Zhong W, Nagarajan UM, Tripathy M, Lee D, Russell AN,
349 Wiesenfeld H, Hillier S, Darville T: **Discovery of blood transcriptional endotypes in**
350 **women with pelvic inflammatory disease.** *J Immunol* 2018, **200**(8):2941-2956.
- 351 9. Zheng X, O'Connell CM, Zhong W, Poston TB, Wiesenfeld HC, Hillier SL, Trent M,
352 Gaydos C, Tseng G, Taylor BD *et al*: **Gene expression signatures can aid diagnosis**
353 **of sexually transmitted infection-induced endometritis in women.** *Front Cell Infect*
354 *Microbiol* 2018, **8**(307):307.
- 355 10. Taylor BD, Zheng X, O'Connell CM, Wiesenfeld HC, Hillier SL, Darville T: **Risk factors**
356 **for *Mycoplasma genitalium* endometritis and incident infection: a secondary data**
357 **analysis of the T cell Response Against Chlamydia (TRAC) Study.** *Sex Transm*
358 *Infect* 2018, **94**(6):414-420.
- 359 11. Roberts DJ, Davis GS, Cole MJ, Naik D, Maru H, Woodford N, Muir P, Horner P, Simms
360 I, Thickett G *et al*: **Prevalence of new variants of *Chlamydia trachomatis* escaping**
361 **detection by the Aptima Combo 2 assay, England, June to August 2019.** *Euro*
362 *Surveill* 2019, **24**(38).
- 363 12. Cole MJ, Davis GS, Fifer H, Saunders JM, Unemo M, Hadad R, Roberts DJ, Fazal M,
364 Day MJ, Minshull J *et al*: **No widespread dissemination of *Chlamydia trachomatis***
365 **diagnostic-escape variants and the impact of *Neisseria gonorrhoeae* positivity on**
366 **the Aptima Combo 2 assay.** *Sex Transm Infect* 2022, **98**(5):366-370.

- 367 13. Hadad R, Jensen JS, Westh H, Gronbaek I, Schwartz LJ, Nielsen L, Vang TM, Nielsen
368 R, Weinreich LS, Skov MN *et al*: **A *Chlamydia trachomatis* 23S rRNA G1523A variant**
369 **escaping detection in the Aptima Combo 2 assay (Hologic) was widespread**
370 **across Denmark in July-September 2019.** *APMIS* 2020, **128**(6):440-444.
- 371 14. Edgar RC: **Search and clustering orders of magnitude faster than BLAST.**
372 *Bioinformatics* 2010, **26**(19):2460-2461.
- 373 15. O'Connell CM, Brochu H, Girardi J, Harrell E, Jones A, Darville T, Sena AC, Peng X:
374 **Simultaneous profiling of sexually transmitted bacterial pathogens, microbiome,**
375 **and concordant host response in cervical samples using whole transcriptome**
376 **sequencing analysis.** *Microb Cell* 2019, **6**(3):177-183.
- 377 16. Hazel A, Ponnaluri-Wears S, Davis GS, Low BS, Foxman B: **High prevalence of**
378 ***Neisseria gonorrhoeae* in a remote, undertreated population of Namibian**
379 **pastoralists.** *Epidemiol Infect* 2014, **142**(11):2422-2432.
- 380 17. Mitchev N, Singh R, Ramsuran V, Ismail A, Allam M, Kwenda S, Mnyameni F, Garrett N,
381 Swe Swe-Han K, Niehaus AJ *et al*: **Assessment of antibiotic resistance and efflux**
382 **pump gene expression in *Neisseria gonorrhoeae* isolates from South Africa by**
383 **quantitative real-time PCR and regression Analysis.** *Int J Microbiol* 2022,
384 **2022**:7318325.
- 385 18. Hokynar K, Rantakokko-Jalava K, Hakanen A, Havana M, Mannonen L, Jokela P,
386 Kurkela S, Lappalainen M, Unemo M, Puolakkainen M: **The Finnish new variant of**
387 ***Chlamydia trachomatis* with a single nucleotide polymorphism in the 23S rRNA**
388 **target escapes detection by the Aptima Combo 2 test.** *Microorganisms* 2019,
389 **7**(8):227.
- 390 19. **R: A Language and Environment for Statistical Computing.** In. Edited by Team RC:
391 R Foundation for Statistical Computing; 2015.

- 392 20. Wickham H: **ggplot: Elegant graphics for data analysis**. New York: Springer-Verlag
393 2016.
- 394 21. Cole JR, Wang Q, Fish JA, Chai B, McGarrell DM, Sun Y, Brown CT, Porras-Alfaro A,
395 Kuske CR, Tiedje JM: **Ribosomal Database Project: data and tools for high**
396 **throughput rRNA analysis**. *Nucleic Acids Res* 2014, **42**(Database issue):D633-642.
- 397 22. Robert CE: **SINTAX: a simple non-Bayesian taxonomy classifier for 16S and ITS**
398 **sequences**. *bioRxiv* 2016:074161.
- 399 23. Cook RL, Hutchison SL, Ostergaard L, Braithwaite RS, Ness RB: **Systematic review:**
400 **noninvasive testing for *Chlamydia trachomatis* and *Neisseria gonorrhoeae***. *Ann*
401 *Intern Med* 2005, **142**(11):914-925.
- 402 24. Centers for Disease Control and Prevention: **Recommendations for the laboratory-**
403 **based detection of *Chlamydia trachomatis* and *Neisseria gonorrhoeae*--2014**.
404 *MMWR Recomm Rep* 2014, **63**(RR-02):1-19.
- 405 25. Unemo M, Hansen M, Hadad R, Puolakkainen M, Westh H, Rantakokko-Jalava K,
406 Thilesen C, Cole MJ, Boiko I, Lan PT *et al*: **Sensitivity, specificity, inclusivity and**
407 **exclusivity of the updated Aptima Combo 2 assay, which provides detection**
408 **coverage of the new diagnostic-escape *Chlamydia trachomatis* variants**. *BMC*
409 *Infect Dis* 2020, **20**(1):419.
- 410 26. Rantakokko-Jalava K, Hokynar K, Hieta N, Keskitalo A, Jokela P, Muotiala A, Jokiranta
411 TS, Kuusela R, Sarkkinen H, Aittoniemi J *et al*: ***Chlamydia trachomatis* samples**
412 **testing falsely negative in the Aptima Combo 2 test in Finland, 2019**. *Euro Surveill*
413 2019, **24**(22).
- 414 27. Smith NH, Holmes EC, Donovan GM, Carpenter GA, Spratt BG: **Networks and groups**
415 **within the genus *Neisseria*: analysis of *argF*, *recA*, *rho*, and 16S rRNA sequences**
416 **from human *Neisseria* species**. *Mol Biol Evol* 1999, **16**(6):773-783.

- 417 28. Abrams AJ, Trees DL, Nicholas RA: **Complete genome sequences of three *Neisseria***
418 ***gonorrhoeae* laboratory reference strains, determined using PacBio single-**
419 **molecule real-time technology.** *Genome Announc* 2015, **3**(5).
- 420 29. Ramsden S, Ovens K, Griffiths J, Muir P, Steele-Nicholson A, Horner PJ:
421 **Environmental contamination by *Chlamydia trachomatis* and *Neisseria***
422 ***gonorrhoeae*: is it time to change our infection control practices? Results of a**
423 **regional study.** *Sex Transm Infect* 2023, **99**(1):35-40.
- 424 30. Katz SS, Danavall DC, Morris MR, Herrod BP, Dale SE, Nye MB, Kersh EN, Kirkcaldy
425 RD, Raphael BH: ***Chlamydia trachomatis* variants escaping detection in the Aptima**
426 **Combo 2 assay in the United States.** *Sex Transm Dis* 2022, **49**(6):448-452.
- 427 31. Puolakkainen M, Mannonen L, Unemo M: **The diagnostic-escape Finnish new variant**
428 **of *Chlamydia trachomatis* first described in 2019 remains present in Finland three**
429 **years after the introduction of an updated Aptima Combo 2 assay.** *Clin Microbiol*
430 *Infect* 2023, **29**(5):658-659.
- 431 32. Bristow CC, McGrath MR, Cohen AC, Anderson LJ, Gordon KK, Klausner JD:
432 **Comparative evaluation of two nucleic acid amplification tests for the detection of**
433 ***Chlamydia trachomatis* and *Neisseria gonorrhoeae* at extragenital sites.** *Sex*
434 *Transm Infect* 2017, **44**(7):398.
- 435 33. Golparian D, Tabrizi SN, Unemo M: **Analytical specificity and sensitivity of the**
436 **APTIMA Combo 2 and APTIMA GC assays for detection of commensal *Neisseria***
437 ***species* and *Neisseria gonorrhoeae* on the Gen-Probe Panther instrument.** *Sex*
438 *Transm Infect* 2013, **40**(2):175-178.
- 439 34. Tabrizi SN, Unemo M, Limnios AE, Hogan TR, Hjelmevoll S-O, Garland SM, Tapsall J:
440 **Evaluation of six commercial nucleic acid amplification tests for detection of**
441 ***Neisseria gonorrhoeae* and other *Neisseria species*.** *J Clinical Microbiol* 2011,
442 **49**(10):3610-3615.

- 443 35. Matysiak C, Cheng A, Kirby JE: **Evaluation of the Abbott Alinity m STI assay for**
444 **diagnosis of the primary causes of sexually transmitted infections in the United**
445 **States.** *Pract Lab Med* 2023, **36**:e00332.
- 446 36. Kriesel JD, Bhatia AS, Barrus C, Vaughn M, Gardner J, Crisp RJ: **Multiplex PCR**
447 **testing for nine different sexually transmitted infections.** *Int J STD AIDS* 2016,
448 **27**(14):1275-1282.
- 449 37. Administration USFD: **Alinity m CMV Assay - P210022.** In.; 2022.
- 450 38. Urra E, Alkorta M, Sota M, Alcalá B, Martínez I, Barrón J, Cisterna R: **Orogenital**
451 **transmission of *Neisseria meningitidis* serogroup C confirmed by genotyping**
452 **techniques.** *Eur J Clin Microbiol Infect Dis* 2005, **24**(1):51-53.
- 453 39. Katz AR, Chasnoff R, Komeya A, Lee MV: ***Neisseria meningitidis* urethritis: a case**
454 **report highlighting clinical similarities to and epidemiological differences from**
455 **gonococcal urethritis.** *Sex Transm Dis* 2011, **38**(5):439-441.
- 456 40. Kanemitsu N, Hayashi I, Satoh N, Hayakawa T, Mitsuya H, Hayase Y, Hiramoto K,
457 Kojima M: **Acute urethritis caused by *Neisseria meningitidis*.** *Int J Urol* 2003,
458 **10**(6):346-347.
- 459 41. Walcher M, Skvoretz R, Montgomery-Fullerton M, Jonas V, Brentano S: **Description of**
460 **an unusual *Neisseria meningitidis* isolate containing and expressing *Neisseria***
461 ***gonorrhoeae*-specific 16S rRNA gene sequences.** *J Clin Microbiol* 2013, **51**(10):3199-
462 3206.
- 463 42. Sukhum KV, Jean S, Wallace M, Anderson N, Burnham CA, Dantas G: **Genomic**
464 **Characterization of Emerging bacterial uropathogen *Neisseria meningitidis*, which**
465 **was misidentified as *Neisseria gonorrhoeae* by nucleic acid amplification testing.**
466 *J Clin Microbiol* 2021, **59**(2).
- 467 43. Klappenbach JA, Saxman PR, Cole JR, Schmidt TM: **rrndb: the Ribosomal RNA**
468 **Operon Copy Number Database.** *Nucleic Acids Res* 2001, **29**(1):181-184.

- 469 44. Ripa T, Nilsson P: **A variant of *Chlamydia trachomatis* with deletion in cryptic**
470 **plasmid: implications for use of PCR diagnostic tests.** *EuroSurveill* 2006,
471 **11(11):E061109.**
- 472 45. Unemo M, Seth-Smith HM, Cutcliffe LT, Skilton RJ, Barlow D, Goulding D, Persson K,
473 Harris SR, Kelly A, Bjartling C *et al*: **The Swedish new variant of *Chlamydia***
474 ***trachomatis*: genome sequence, morphology, cell tropism and phenotypic**
475 **characterization.** *Microbiology*, **156**(Pt 5):1394-1404.
- 476 46. Karellis A, Naeem F, Nair S, Mallya SD, Routy JP, Gahagan J, Yansouni CP, Kim J, Pai
477 NP: **Multiplexed rapid technologies for sexually transmitted infections: a**
478 **systematic review.** *Lancet Microbe* 2022, **3**(4):e303-e315.
- 479

Table 2. *Neisseria sp.* transcripts detected by 16S ASV analysis and genes detected by qPCR in diagnostic-discrepant or NG+ TRAC participants.

Sample ID	Diagnostic test		16S rRNA read counts				qPCR†		
	Cervix	Endo	ZOtu95: N_gonorrhoeae	ZOtu141: N_subflava	ZOtu264: N_mucosa	ZOtu1566: N_elongata	16S	23S	ParA
3-121	-	-	130	0	0	0	+	+	-
3-140	-	-	123	0	0	0	+	+	+
3-146	-	-	106	0	0	0	+	+	ND
3-151	-	-	6	0	0	0	+	-	+
3-209	-	-	1	0	0	0	-	+	ND
3-012	+	-	471	0	0	0	+	+	+
3-026	+	-	10	0	0	0	-	-	-
3-052	+	-	10	0	0	0	-	+	-
3-089	+	-	24	0	0	0	-	+	+
3-091	+	-	6	0	0	0	+	+	+
3-112	+	-	1032	0	0	0	+	+	+
3-114	+	-	85	0	0	0	-	-	-
3-120	+	-	19	211	131	0	-	+	-
3-122	+	-	110	0	0	0	+	+	+
3-124	+	-	927	0	0	0	-	+	-
3-133	+	-	3	0	0	0	-	-	-
3-136	+	-	2	0	1	0	+	+	-
3-177	+	-	180	0	0	0	+	+	+
3-208	+	-	1151	0	0	0	-	+	-
3-212	+	-	9	0	0	0	+	+	+
3-223	+	-	206	0	0	0	+	+	+
3-235	+	-	349	0	0	0	+	+	+

†Assay performed with diagnostic swab eluate or vaginal swab template used for 16S rRNA microbiome analysis. ND not done because specimen was insufficient or unavailable.

480


481

482

483

484

485



486

487 **Figure 1. STI-derived 16S transcripts detected in vaginal swabs.** a) 16S rRNA gene read
488 counts of STIs stratified by infection status at enrollment. b) Concordance between CT 16S rRNA
489 gene read counts versus CT burden by qPCR, where samples are colored by infection status at
490 enrollment. A LOESS curve is shown in red and Spearman correlation in the bottom-right. CT,
491 *Chlamydia trachomatis*; GC, *N. gonorrhoeae*; MG, *M. genitalium*

492

493

```
          1450      1460      1470      1480      1490      1500      1510      1520      1530      1540      1550      1560      1570      1580
Reference 1446  g t c c g t a g a g c g a t g a g a a c g g t t a g t a g g c a a a t c c g c t a a c a t a a g a t c a g g t c g c g a t c a a g g g g a a t c t t c g g a g g a a c c g a t g g t g t g g a g c g a g g c t t t c a a g a a t a a t t t c t a g c t g t t g a t g g t g a c c g t
3.144 21    g t c c g t a g a g c g a t g a g a a c g g t t a g t a g g c a a a t c c g c t a a c a t a a g a t c a g g t c g c g a t c a a g g g g a a t c t t c g g a g g a a c c g a t g g t g t g g a g c g a g g c t t t c a a g a a t a a t t t c t a g c t g t t g a t g g t g a c c g t
3.145 22    g t c c g t a g a g c g a t g a g a a c g g t t a g t a g g c a a a t c c g c t a a c a t a a g a t c a g g t c g c g a t c a a g g g g a a t c t t c g g a g g a a c c g a t g g t g t g g a g c g a g g c t t t c a a g a a t a a t t t c t a g c t g t t g a t g g t g a c c g t
3.148 23    g t c c g t a g a g c g a t g a g a a c g g t t a g t a g g c a a a t c c g c t a a c a t a a g a t c a g g t c g c g a t c a a g g g g a a t c t t c g g a g g a a c c g a t g g t g t g g a g c g a g g c t t t c a a g a a t a a t t t c t a g c t g t t g a t g g t g a c c g t
3.226 22    g t c c g t a g a g c g a t g a g a a c g g t t a g t a g g c a a a t c c g c t a a c a t a a g a t c a g g t c g c g a t c a a g g g g a a t c t t c g g a g g a a c c g a t g g t g t g g a g c g a g g c t t t c a a g a a t a a t t t c t a g c t g t t g a t g g t g a c c g t
3.209 22    g t c c g t a g a g c g a t g a g a a c g g t t a g t a g g c a a a t c c g c t a a c a t a a g a t c a g g t c g c g a t c a a g g g g a a t c t t c g g a g g a a c c g a t g g t g t g g a g c g a g g c t t t c a a g a a t a a t t t c t a g c t g t t g a t g g t g a c c g t
3.101 22    g t c c g t a g a g c g a t g a g a a c g g t t a g t a g g c a a a t c c g c t a a c a t a a g a t c a g g t c g c g a t c a a g g g g a a t c t t c g g a g g a a c c g a t g g t g t g g a g c g a g g c t t t c a a g a a t a a t t t c t a g c t g t t g a t g g t g a c c g t
3.201 22    g t c c g t a g a g c g a t g a g a a c g g t t a g t a g g c a a a t c c g c t a a c a t a a g a t c a g g t c g c g a t c a a g g g g a a t c t t c g g a g g a a c c g a t g g t g t g g a g c g a g g c t t t c a a g a a t a a t t t c t a g c t g t t g a t g g t g a c c g t
```

494

495 **Figure 2. Portion of sequence alignment of V3 amplified PCR products from discrepant**

496 **TRAC participant specimens revealing a g to a substitution at 1523 in the 23S rDNA locus.**

497 PCR products from two representative CT+ samples, as determined by AC2 diagnostic test were

498 wild type at this position (data not shown).

499